Hereditary Oncology Testing
Test in Focus
In this "Test in Focus" episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., discusses Mayo Clinic Laboratories’ new hereditary oncology test offerings, which use next-generation sequencing to detect germline alterations associated with increased risk for various cancers. Our comprehensive panels, disease-specific panels, and single gene assays leverage the clinical expertise of Mayo Clinic physicians, enabling individualized insights on a patient’s risk of developing secondary cancers or a hereditary cancer syndrome.
“We know inherited genetic alterations contribute to about 10% to 20% of cancers overall,” Dr. Shen says. “However, more studies are showing that universal genetic testing actually detects more patients with hereditary cancer syndromes than a guideline-based approach.”
Test results can indicate the likelihood of a clinical diagnosis of a hereditary cancer syndrome, advance understanding of a patient’s risk of developing additional cancers, assist in management and treatment decisions, and rule out hereditary causes, Dr. Shen says. The biggest benefit of using Mayo Clinic testing, however, is access to expert-backed testing across the oncological spectrum.
“Cancers can result from both somatic and germline mutations,” Dr. Shen says. “This series of new genetic panels completes our comprehensive cancer testing menu and allows us to offer a one-stop shop genetic service to physicians and cancer patients.”
Listen to learn more.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
COMCP | Hereditary Common Cancer Panel
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.